medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Number 4

<< Back Next >>

Ann Hepatol 2012; 11 (4)

Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma

Khattab MA, Eslam M, Mousa YI, Ela-adawy N, Fathy S, Shatat M, Abd-Aalhalim H, Kamal A, Sharawe MA

Language: English
References: 32
Page: 487-494
PDF size: 111.60 Kb.


ABSTRACT

Background and aim. Metabolic syndrome is recognised as a potential risk factor for the development of hepatocellular carcinoma (HCC). The association between metabolic factors and hepatitis C (HCV)-related HCC has not yet been well clarified. This study was conducted to elucidate the role of metabolic factors in HCV-related HCC. Material and methods. We recruited 147 HCC patients and compared them with 147 matched CHC patients and 320 controls. The plasma levels of homeostasis model assessment-IR (HOMA-IR), adiponectin and lipids for all participants were assessed. Results. The HCC group showed significantly higher levels of insulin, glucose, HOMA-IR and adiponectin as well as lower levels of total cholesterol, HDL-C, LDL-C, and triglycerides compared with the matched CHC patients and controls. HOMA-IR did not correlate with pathologic features of HCC, whereas serum adiponectin levels correlated positively with the size of tumour nodules (P = 0.009). Based on stepwise logistic regression analysis, age (OR: 1.456, 95% CI: 1.072- 1.979, P ‹ 0.01), HOMA-IR (OR: 2.50, 95% CI: 1.70-3.69, P = 0.001), and adiponectin (OR: 1.585, 95% CI: 1.269- 1.980, P = 0.001) were independently associated with HCC. Conclusions. Metabolic abnormalities are closely associated with the occurrence and development of HCV-related HCC. Patients with CHC and high serum adiponectin levels face a higher risk of developing liver cancer. Insulin resistance, as measured by HOMA-IR, is significantly associated with HCV-related HCC.


REFERENCES

  1. Ferlay J, Bray F, Pisani P. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Press; Lyon: 2004. IARC CancerBase No. 5. version 2.0.

  2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.

  3. Bosch FX, Ribes J, Cleries R, Díaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9: 191-211.

  4. Eslam M, Khattab MA, Harrison SA. Insulin resistance and hepatitis C: an evolving story. Gut 2011; 60(8): 1139-51.

  5. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43(2 Suppl. 1): S99-S112.

  6. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 2004; 27: 2444-9.

  7. Wedemeyer I, Bechmann LP, Odenthal M, Jochum C, Marquitan G, Drebber U, Gerken G, et al. Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: therapeutic implications for hepatitis C. J Hepatol 2009; 50: 140-9.

  8. Huang H, Park PH, McMullen MR, Nagy LE. Mechanisms for the anti-inflammatory effects of adiponectin in macrophages. J Gastroenterol Hepatol 2008; 23(Suppl. 1): S50-S53.

  9. Adachi M, Brenner DA. High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate activated protein kinase. Hepatology 2008; 47: 677-85.

  10. Khattab M, Shatat MS, Eslam M, Mayada A, Hussein A, Gaber S, Harrison SA. Insulin resistance in hepatitis C genotype 4 is partially mediated by virus-Specific changes in adipocytokines. J Hepatol 2011; 54: S458 A.

  11. Khattab M, Shatat MS, Eslam M, Mayada A, Hussein A, Gaber S, Harrison SA. Association of Serum Adipocytokines with Liver Injury in Patients with Chronic Hepatitis C Genotype 4. J Hepatol 2011; 54: S458-S459A.

  12. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009; 50: 957-69.

  13. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.

  14. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.

  15. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, et al; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-30.

  16. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-38.

  17. Wolk A, Gridley G, Svensson M, Nyrén O, McLaughlin JK, Fraumeni JF, Adam HO. prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001; 12: 13-21.

  18. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001; 60(1): 91-106.

  19. Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G, Groyer A. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug induced apoptosis. Biochem Pharmacol 2004; 68: 1003-15.

  20. Sharma D, Wang J, Fu PP, Sharma S, Nagalingam A, Mells J, Handy J, et al. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology 2010; 52(5): 1713-22.

  21. Arano T, Nakagawa H, Tateishi R, Ikeda H, Uchino K, Enooku K, Goto E, et al. Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patients. Int J Cancer 2010.

  22. Liu CJ, Chen PJ, Lai MY, Liu CH, Chen CL, Kao JH, Chen DS. High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection. Hepatol Int 2009; 3: 364-70.

  23. Chen X, Wang Y. Adiponectin and breast cancer. Med Oncol 2010 [Epub ahead of print].

  24. Rzepka-Go’rska I, Bedner R, Cymbaluk-P1oska A, Chudecka- G1az A. Serum adiponectin in’relation to endometrial cancer and endometrial hyperplasia with atypia in obese women. Eur J Gynaecol Oncol 2008; 29(6): 594-7.

  25. Michalakis K, Williams CJ, Mitsiades N, Blakeman J, Balafouta- Tselenis S, Giannopoulos A, Mantzoros CS. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev 2007; 16(2): 308-13.

  26. Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gómez- Reino JJ, Gualillo O. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1198-201.

  27. Haugen F, Ranheim T, Harsem NK, Lips E, Staff AC, Drevon CA. Increased plasma levels of adipokines in preeclampsia: relationship to placenta and adipose tissue gene expression. Am J Physiol Endocrinol Metab 2006; 290: E326- E333.

  28. Kollerits B, Fliser D, Heid IM, Ritz E, Kronenberg F. Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney Int 2007; 71: 1279-86.

  29. Michiel DF, Oppenheim JJ. Cytokines as positive and negative regulators of tumor promotion and progression. Semin Cancer Biol 1992; 3(1): 3-15.

  30. Siemianowicz K, Gminski J, Stajszczyk M, Wojakowski W, Goss M, Machalski M, Telega A, et al. Serum total cholesterol and triglycerides levels in patients with lung cancer. Int J Mol Med 2000; 5(2): 201-5.

  31. Jiang J, Nilsson-Ehle P, Xu N. Influence of liver cancer on lipid and lipoprotein metabolism. Lipids Health Dis 2006; 5: 4.

  32. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, Wang LY, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a followup study in Taiwan. Gastroenterology 2008; 135(1): 111-12.




2020     |     www.medigraphic.com